PT-141

Buy PT-141 Online

Book Now

Questions about peptides? Click here to schedule a free consultation with a physician.

x
Secure Encrypted Payments

Buy PT-141 online with a valid prescription and compare current listed pricing, product presentations, and safety basics before you place an order. This page is built for customers checking PT-141 price and access details, available form or strength options, and whether the selected product matches their prescription. When available, US delivery from Canada can support cross-border access while keeping prescriber details ready for any required check.

PT-141 is a prescription sexual-health product also known as bremelanotide. Before checkout, review the selected presentation, quantity, route of use, handling notes, and important warnings so the order reflects what your clinician prescribed.

PT-141 Price and Available Options

Current listed pricing should be compared against the exact product option selected on the page. For PT-141, that means checking the listed presentation, strength or concentration if shown, total contents, quantity, and any separate product entries before you move forward. A lower-looking amount on one listing may reflect a different form, pack size, or total volume, so compare like with like.

Searches for pt 141 nasal spray, pt 141 injection, and pt 141 peptide can refer to different presentations. Do not treat those terms as interchangeable unless your prescription and the product listing match. If the page shows a selector, confirm the route, strength, and quantity before checkout rather than relying on a product name alone.

Quick tip: Match the product presentation first, then compare the listed price.

PT-141 cost can also be affected by cash-pay status, required quantity, and whether supporting information is needed before the order can proceed. If you are paying without insurance, focus on the displayed product details and any checkout notes instead of assuming that another peptide listing uses the same pricing basis.

How to Buy PT-141 Online

To buy PT-141 online, start by choosing the product option that matches the prescription. Keep the prescriber’s name, contact information, and directions available in case the order needs confirmation. A valid prescription is required, and prescription details may be reviewed or verified when needed before the selected product is supplied.

The order path is easiest when the product listing, route, and quantity line up with the directions you were given. BorderFreeHealth supports cash-pay, cross-border prescription options, and US shipping from Canada may be part of the access pathway when shown for this product. Supporting documents may be requested if the order details are incomplete or unclear.

Use the checkout process to review your selected item, not to decide a new dose or route. If the prescription says injection, nasal spray, or another specific presentation, the product option should reflect that wording. If it does not, contact your clinician before changing the order.

What This Peptide Is Used For

PT-141, also called bremelanotide, is a melanocortin receptor agonist (a medicine that activates certain brain signaling pathways). It is best known for its role in sexual desire disorders, especially the FDA-approved bremelanotide injection used for acquired, generalized hypoactive sexual desire disorder in premenopausal women.

Some online searches discuss PT-141 for men, erectile dysfunction, or libido support. Those uses are not the same as the approved labeled indication and should be handled by a clinician who knows your medical history. This product is not a substitute for a full evaluation of low desire, erectile problems, relationship stress, medication effects, hormone issues, or cardiovascular risk.

PT-141 works differently from phosphodiesterase type 5 inhibitors such as sildenafil or tadalafil. Those medicines primarily affect blood flow, while bremelanotide acts through melanocortin pathways. That difference matters when comparing options, because route of use, timing, side effects, and interaction concerns are not identical.

Product Details to Match Before Checkout

The safest order is the one that mirrors the written prescription. Review the product name, selected form, strength details, total amount, and directions before completing checkout. If any detail is missing or does not match, pause and clarify it rather than guessing.

Detail to checkWhy it matters
Form or routeInjection, nasal spray, or another presentation may not be interchangeable.
Strength or concentrationTotal contents can differ from the amount used at one time.
Quantity or pack countThe listed quantity affects how long the supply may last.
Directions suppliedUse timing and maximum frequency should come from the prescriber.
Storage instructionsHandling needs can differ by formulation and packaging.

PT-141 10mg searches often focus on vial size or total contents, but total milligrams do not automatically equal one dose. Concentration, volume, and prescribed directions determine how a product is used. Do not calculate or change dosing from a product title alone.

Why it matters: Similar product names can hide meaningful differences in route, contents, and directions.

Dosing Questions and Timing Expectations

PT-141 dosage questions should be answered by the prescribing clinician or the official product instructions. Do not increase the amount, repeat use sooner than directed, or combine routes because an expected effect did not happen. Timing can vary, and sexual-health medicines should not be planned around a guaranteed window.

People often ask how long a PT-141 injection lasts. The answer depends on the product, the prescribed directions, individual response, and side effects. Your clinician can explain what to expect for the specific presentation you are using and what to do if the response is too strong, too weak, or uncomfortable.

Tell your clinician if nausea, flushing, headache, vomiting, dizziness, skin darkening, or blood-pressure symptoms occur. That information helps them decide whether continued use, monitoring, or a different option is more appropriate. Do not use online calculators as a replacement for personal instructions.

Storage, Handling, and Travel Basics

Storage instructions can vary by formulation. Follow the product label, pharmacy directions, and any carton instructions that come with the selected item. If refrigeration, protection from light, beyond-use dating, or disposal instructions are listed, those details should guide how you store and transport the product.

If the product is supplied as an injection, check whether needles, syringes, alcohol swabs, or a sharps container are needed. Do not reuse needles or share devices. Inspect the product before use according to the instructions, and do not use it if packaging is damaged, the date has passed, or the appearance is not as described.

If the product is supplied as a nasal spray, review priming, cleaning, and device-use directions carefully. Nasal devices should not be shared. If a spray, vial, or device is exposed to temperature extremes during travel, ask a healthcare professional whether it can still be used safely.

When traveling, keep prescription labels and directions with the product. Pack it in a way that protects the presentation from heat, freezing, breakage, and contamination. Planning ahead is especially important for products that require supplies or temperature control.

Safety Basics Before Ordering

PT-141 can cause side effects. Commonly discussed effects with bremelanotide include nausea, flushing, headache, vomiting, injection-site reactions, and dizziness. Some people may also notice darkening of the gums, face, or other skin areas after repeated exposure.

Bremelanotide can temporarily raise blood pressure and lower heart rate after use. It is not appropriate for people with uncontrolled high blood pressure or known cardiovascular disease according to official safety information for the approved injection. If you have heart disease, chest pain, fainting, stroke history, or poorly controlled blood pressure, discuss those risks before using it.

Seek urgent medical help for severe chest pain, shortness of breath, fainting, signs of an allergic reaction, or symptoms that feel dangerous. For less urgent but persistent side effects, contact the prescriber before the next use. Reporting side effects early can help prevent repeated exposure to a product that may not suit you.

Alcohol, dehydration, sleep loss, and other medicines can complicate how someone feels after sexual-health treatment. Keep a simple record of timing, side effects, and any other medicines taken that day. Bring that information to follow-up visits rather than changing the dose on your own.

Interactions and Monitoring Cautions

Ask a clinician before combining PT-141 with sildenafil, tadalafil, nitrates, blood-pressure medicines, or other sexual-health products. Combining treatments can increase side effects or make it harder to identify which product caused a reaction. Cardiovascular history matters because sexual activity and some medicines can both affect the heart and blood vessels.

Bremelanotide may slow gastric emptying, which can affect how certain oral medicines are absorbed. The official labeling also highlights concern with oral naltrexone because reduced exposure could lead to treatment failure. Share a full medication list, including over-the-counter products and supplements, before starting therapy.

Monitoring is especially important if you have blood pressure concerns, nausea that limits eating or hydration, or repeated flushing and dizziness. Your clinician may ask about response, side effects, and how often the product is being used. That follow-up is part of using a prescription sexual-health treatment responsibly.

Compare Related Sexual Health Options

PT-141 may be one option among several sexual-health treatments, but the right comparison depends on the condition being treated. Browse the Hypoactive Sexual Desire Disorder collection if your prescription relates to low desire. Addyi is a different prescribed option for certain patients, and the Addyi product page can help you compare route and treatment style.

If the main concern is erections rather than desire, the Erectile Dysfunction product list may be a more relevant place to compare prescribed options. Blood-pressure questions are common with sexual-health medicines, so the Does Cialis Lower Blood Pressure resource can help frame questions for a clinician. For broader risk checks, Regular Health Screenings For Men is useful when symptoms may overlap with heart, hormone, or metabolic health.

Comparisons should focus on indication, route, timing, side effects, and safety fit. Avoid choosing between products based only on anecdotes or search popularity. A medicine used for desire may not solve a blood-flow problem, and a medicine used for erections may not address low sexual interest.

Authoritative Sources

For clinical safety details, start with the Mayo Clinic bremelanotide monograph.

For pharmacology background, the PubMed review of PT-141 summarizes melanocortin-receptor research.

This content is for informational purposes only and is not a substitute for professional medical advice.

Express Shipping - from $25.00

Shipping with this method takes 3-5 days

Prices:
  • Dry-Packed Products $25.00
  • Cold-Packed Products $35.00
Shipping Countries:
  • United States (all contiguous states**)
  • Worldwide (excludes some countries***)

Standard Shipping - $15.00

Shipping with this method takes 5-10 days

Prices:
  • Dry-Packed Products $15.00
  • Not available for Cold-Packed products
Shipping Countries:
  • United States (all contiguous states**)
  • Worldwide (excludes some countries***)

Rewards Program

Earn points on birthdays, product orders, reviews, friend referrals, and more! Enjoy your medication at unparalleled discounts while reaping rewards for every step you take with us.

You can read more about rewards here.

POINT VALUE

100 points
1 USD

How to earn points

  • 1Register and/or Login
    Create an account and start earning.
  • 2Earn Rewards
    Earn points every time you shop or perform certain actions.
  • 3Redeem
    Redeem points for exclusive discounts.

You Might Also Like

Epithalon

$47.49

  • In Stock
  • Express Shipping
Our Price $47.49
Select options This product has multiple variants. The options may be chosen on the product page
MOTS-c

$94.99

  • In Stock
  • Express Shipping
Our Price $94.99
Select options This product has multiple variants. The options may be chosen on the product page
TB500

$61.74

  • In Stock
  • Express Shipping
Our Price $61.74
Select options This product has multiple variants. The options may be chosen on the product page
BPC-157

$47.49

  • In Stock
  • Express Shipping
Our Price $47.49
Select options This product has multiple variants. The options may be chosen on the product page

Peptide Screening Form

Patient Information

Please provide your basic demographic information.

Type your date of birth in MM/DD/YYYY format.

Peptides of Interest

Peptides of Interest

Select the peptides you are interested in or have been recommended.

Medical History & Screening

Medical History & Screening

Please indicate if any of the following apply to you. Red flag alerts will appear if a condition contraindicates any of the available peptide therapies.

Contraindicated for CJC-1295: Growth hormone-releasing peptides like CJC-1295 are contraindicated in patients with active cancer because they may promote cell proliferation and tumor growth.

Contraindicated for Ipamorelin: Ipamorelin stimulates growth hormone release, which may promote tumor growth and cell proliferation in active cancers.

Contraindicated for Sermorelin: Sermorelin increases growth hormone production, which may stimulate growth of existing tumors.

Contraindicated for BPC-157: BPC-157 promotes angiogenesis (new blood vessel formation), which could support tumor growth and metastasis in active cancers.

Contraindicated for AOD-9604: Although AOD-9604 is a modified GH fragment, it may still interact with growth-related pathways in patients with active malignancies.

Contraindicated for TB-500 (Thymosin Beta-4): TB-500 promotes cell migration and angiogenesis, which may facilitate tumor growth and metastasis in active cancers.

Contraindicated for GHK-Cu: GHK-Cu promotes angiogenesis and tissue remodeling, which may support tumor growth in patients with active cancer.

Contraindicated for Epithalon (Epitalon): Epithalon stimulates telomerase activity. Cancer cells exploit telomerase to achieve immortality, potentially accelerating tumor growth.

Contraindicated for Semax: Semax has neurotrophic properties that promote cell growth, which may be concerning in patients with active malignancies.

Contraindicated for MOTS-c: MOTS-c influences cellular metabolism and AMPK pathways. Effects on cancer cell metabolism are not fully understood.

Contraindicated for Tesamorelin: Tesamorelin stimulates growth hormone release, which may promote tumor growth in patients with active malignancies.

Contraindicated for Hexarelin: Hexarelin stimulates growth hormone release, which may promote tumor growth and cell proliferation.

Contraindicated for GHRP-6: GHRP-6 stimulates growth hormone release, which may promote tumor growth in active cancers.

Contraindicated for GHRP-2: GHRP-2 stimulates growth hormone release, which may promote tumor growth in active malignancies.

Contraindicated for Melanotan II: Melanotan II stimulates melanocyte activity. In patients with skin cancers, particularly melanoma, it may accelerate disease progression.

Contraindicated for Dihexa: Dihexa activates hepatocyte growth factor (HGF) pathways, which can promote tumor growth and metastasis.

Contraindicated for Kisspeptin-10: Kisspeptin-10 influences reproductive hormone pathways. Hormone-sensitive cancers may be affected by altered GnRH and gonadotropin levels.

Contraindicated for Humanin: Humanin has anti-apoptotic properties that may protect cancer cells from programmed cell death, potentially supporting tumor survival.

Contraindicated for Retatrutide: Retatrutide acts on multiple metabolic pathways including GLP-1 and GIP receptors. Its effects on cell proliferation in patients with active malignancies have not been fully characterized.

Contraindicated for CJC-1295: CJC-1295 stimulates growth hormone release, which can increase IGF-1 levels. Elevated IGF-1 has been associated with cancer recurrence.

Contraindicated for Ipamorelin: The growth hormone and IGF-1 elevation from Ipamorelin may increase the risk of cancer recurrence.

Contraindicated for Sermorelin: Growth hormone stimulation from Sermorelin elevates IGF-1, which has been linked to increased cancer recurrence risk.

Contraindicated for BPC-157: The pro-angiogenic properties of BPC-157 may potentially support recurrence by promoting blood vessel growth that could feed dormant cancer cells.

Contraindicated for TB-500 (Thymosin Beta-4): The pro-angiogenic and cell-migration properties of TB-500 may increase the risk of cancer recurrence.

Contraindicated for Epithalon (Epitalon): Telomerase activation from Epithalon may increase the risk of cancer recurrence by supporting abnormal cell survival.

Contraindicated for Tesamorelin: Growth hormone and IGF-1 elevation from Tesamorelin may increase risk of cancer recurrence.

Contraindicated for Hexarelin: Elevated growth hormone and IGF-1 from Hexarelin may increase risk of cancer recurrence.

Contraindicated for GHRP-6: Growth hormone and IGF-1 elevation from GHRP-6 may increase risk of cancer recurrence.

Contraindicated for GHRP-2: Elevated IGF-1 from GHRP-2-stimulated growth hormone may increase cancer recurrence risk.

Contraindicated for Melanotan II: Melanocortin stimulation from Melanotan II may increase melanoma recurrence risk in patients with skin cancer history.

Contraindicated for Dihexa: HGF pathway activation from Dihexa may increase cancer recurrence risk through pro-growth signaling.

Contraindicated for Humanin: The cytoprotective effects of Humanin may increase cancer recurrence risk by inhibiting apoptosis in dormant cancer cells.

Contraindicated for Retatrutide: GLP-1 receptor agonists have been linked to thyroid C-cell tumors in animal studies. Retatrutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma.

Contraindicated for Retatrutide: Retatrutide is contraindicated in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) due to the risk of medullary thyroid carcinoma associated with GLP-1 receptor agonists.

Contraindicated for CJC-1295: CJC-1295 has not been studied in pregnancy and may affect fetal development through altered growth hormone levels.

Contraindicated for Ipamorelin: Ipamorelin has not been studied in pregnancy. Altered growth hormone levels may impact fetal development.

Contraindicated for Sermorelin: Sermorelin is not approved for use during pregnancy due to potential effects on fetal growth and development.

Contraindicated for BPC-157: BPC-157 has not been adequately studied in human pregnancy. Its tissue-modulating effects may pose risks to fetal development.

Contraindicated for Thymosin Alpha-1: Immune modulation during pregnancy may disrupt the delicate immune tolerance required for fetal development.

Contraindicated for PT-141: PT-141 is contraindicated in pregnancy as melanocortin receptor activation may affect fetal development.

Contraindicated for AOD-9604: AOD-9604 has not been studied in pregnancy. Its effects on fetal metabolism are unknown.

Contraindicated for TB-500 (Thymosin Beta-4): TB-500 has not been studied in pregnancy. Its tissue-remodeling effects may pose risks to fetal development.

Contraindicated for GHK-Cu: GHK-Cu has not been studied in pregnancy. Copper peptide effects on fetal development are unknown.

Contraindicated for Epithalon (Epitalon): Epithalon has not been studied in pregnancy. Effects on fetal cellular development are unknown.

Contraindicated for Selank: Selank has not been studied in pregnancy. Its neuroactive effects may impact fetal brain development.

Contraindicated for Semax: Semax has not been studied in pregnancy. Its neuroactive and hormonal effects may affect fetal development.

Contraindicated for DSIP (Delta Sleep-Inducing Peptide): DSIP has not been studied in pregnancy. Its neuroendocrine effects may impact fetal development.

Contraindicated for MOTS-c: MOTS-c has not been studied in pregnancy. Its metabolic effects may impact fetal development.

Contraindicated for Tesamorelin: Tesamorelin is contraindicated in pregnancy due to potential effects on fetal growth from altered growth hormone levels.

Contraindicated for Hexarelin: Hexarelin has not been studied in pregnancy. Altered growth hormone levels may impact fetal development.

Contraindicated for GHRP-6: GHRP-6 has not been studied in pregnancy. Growth hormone modulation may affect fetal development.

Contraindicated for GHRP-2: GHRP-2 has not been studied in pregnancy. Its effects on fetal growth and development are unknown.

Contraindicated for Melanotan II: Melanotan II is contraindicated in pregnancy due to unknown effects on fetal development from melanocortin receptor activation.

Contraindicated for LL-37: LL-37 has not been studied in pregnancy. Immune modulation may disrupt maternal-fetal immune tolerance.

Contraindicated for KPV: KPV has not been studied in pregnancy. Its immunomodulatory effects may impact fetal development.

Contraindicated for Dihexa: Dihexa has not been studied in pregnancy. Its neurotrophic and growth factor effects may impact fetal development.

Contraindicated for 5-Amino-1MQ: 5-Amino-1MQ has not been studied in pregnancy. Its metabolic enzyme inhibition may affect fetal development.

Contraindicated for SS-31 (Elamipretide): SS-31 has not been studied in pregnancy. Its effects on mitochondrial function in developing tissues are unknown.

Contraindicated for PE-22-28: PE-22-28 has not been studied in pregnancy. Its neurogenic effects may impact fetal brain development.

Contraindicated for Kisspeptin-10: Kisspeptin-10 directly affects reproductive hormones and GnRH signaling. Use during pregnancy may disrupt hormonal balance critical for fetal development.

Contraindicated for Humanin: Humanin has not been studied in pregnancy. Its effects on fetal cellular development and apoptosis pathways are unknown.

Contraindicated for KLOW: KLOW has not been studied in pregnancy. Effects on fetal development are unknown.

Contraindicated for GLOW: GLOW has not been studied in pregnancy. Effects on fetal development are unknown.

Contraindicated for Retatrutide: Retatrutide has not been studied in pregnancy. GLP-1 receptor agonists may affect fetal development and maternal glucose regulation.

Contraindicated for CJC-1295: Safety of CJC-1295 during breastfeeding has not been established. Growth hormone modulation could affect lactation.

Contraindicated for BPC-157: Insufficient safety data exists for BPC-157 use during breastfeeding.

Contraindicated for PT-141: Safety of PT-141 during breastfeeding has not been established.

Contraindicated for AOD-9604: Insufficient safety data for AOD-9604 during breastfeeding.

Contraindicated for Selank: Safety of Selank during breastfeeding has not been established. Neuroactive peptides may pass into breast milk.

Contraindicated for DSIP (Delta Sleep-Inducing Peptide): Safety of DSIP during breastfeeding has not been established.

Contraindicated for KPV: Safety of KPV during breastfeeding has not been established.

Contraindicated for 5-Amino-1MQ: Safety of 5-Amino-1MQ during breastfeeding has not been established.

Contraindicated for PE-22-28: Safety of PE-22-28 during breastfeeding has not been established. Neuroactive peptides may pass into breast milk.

Contraindicated for Kisspeptin-10: Kisspeptin-10 modulates reproductive hormones, which may affect lactation and hormonal balance during breastfeeding.

Contraindicated for KLOW: Safety of KLOW during breastfeeding has not been established.

Contraindicated for GLOW: Safety of GLOW during breastfeeding has not been established.

Contraindicated for Retatrutide: Safety of Retatrutide during breastfeeding has not been established. It is unknown whether the peptide is excreted in breast milk.

Contraindicated for CJC-1295: Growth hormone elevation from CJC-1295 can worsen diabetic retinopathy by promoting abnormal blood vessel growth in the retina.

Contraindicated for Ipamorelin: Elevated growth hormone from Ipamorelin can accelerate retinal neovascularization in diabetic retinopathy.

Contraindicated for GHRP-6: Elevated growth hormone from GHRP-6 can worsen diabetic retinopathy by promoting abnormal blood vessel growth.

Contraindicated for GHRP-2: Growth hormone elevation from GHRP-2 can accelerate retinal neovascularization in diabetic retinopathy.

Contraindicated for Retatrutide: Rapid improvement in glycemic control from Retatrutide may temporarily worsen diabetic retinopathy. Close ophthalmologic monitoring is recommended.

Contraindicated for CJC-1295: Growth hormone-releasing peptides can elevate intracranial pressure, worsening existing intracranial hypertension.

Contraindicated for Sermorelin: Growth hormone elevation from Sermorelin can increase intracranial pressure.

Contraindicated for Tesamorelin: Growth hormone elevation from Tesamorelin can increase intracranial pressure.

Contraindicated for CJC-1295: CJC-1295 acts on the pituitary gland. Existing pituitary disorders may lead to unpredictable or dangerous hormone responses.

Contraindicated for Ipamorelin: Ipamorelin directly stimulates the pituitary gland. Pre-existing pituitary conditions may result in adverse hormonal responses.

Contraindicated for Sermorelin: Sermorelin requires a functioning pituitary gland. Pituitary disorders may prevent proper response or cause adverse effects.

Contraindicated for DSIP (Delta Sleep-Inducing Peptide): DSIP affects neuroendocrine signaling involving the pituitary gland. Pre-existing pituitary conditions may lead to unpredictable effects.

Contraindicated for Tesamorelin: Tesamorelin acts directly on the pituitary gland. Pre-existing pituitary disorders may cause unpredictable hormonal responses.

Contraindicated for Hexarelin: Hexarelin acts on the pituitary gland. Pre-existing pituitary conditions may result in adverse hormonal responses.

Contraindicated for GHRP-6: GHRP-6 acts directly on the pituitary gland. Pre-existing disorders may cause adverse hormonal effects.

Contraindicated for GHRP-2: GHRP-2 directly stimulates the pituitary gland. Pre-existing pituitary disorders may cause unpredictable responses.

Contraindicated for Kisspeptin-10: Kisspeptin-10 stimulates the hypothalamic-pituitary axis. Pre-existing pituitary disorders may lead to unpredictable hormonal responses.

Contraindicated for Thymosin Alpha-1: Thymosin Alpha-1 stimulates T-cell activity and immune response. In patients with autoimmune conditions, this can trigger disease flares.

Contraindicated for Epithalon (Epitalon): Epithalon may modulate immune function through its effects on the pineal gland, potentially exacerbating autoimmune conditions.

Contraindicated for Melanotan II: Melanotan II modulates immune function through melanocortin receptors, potentially exacerbating autoimmune conditions.

Contraindicated for LL-37: LL-37 is a potent immune activator. In autoimmune conditions, it may trigger inflammatory flares and worsen disease activity.

Contraindicated for KLOW: Peptide blends may modulate immune function. Patients with autoimmune conditions should consult their provider before use.

Contraindicated for GLOW: Peptide blends may modulate immune function. Patients with autoimmune conditions should consult their provider before use.

Contraindicated for Thymosin Alpha-1: Thymosin Alpha-1 enhances immune function, which directly counteracts immunosuppressive therapy required to prevent organ rejection.

Contraindicated for LL-37: LL-37 enhances immune function, which may counteract immunosuppressive therapy in transplant recipients.

Contraindicated for PT-141: PT-141 affects blood pressure and cardiovascular function. Patients with heart disease face increased risk of adverse cardiac events.

Contraindicated for Hexarelin: Hexarelin has been shown to affect cardiac function and cortisol release. Patients with cardiovascular disease should use caution.

Contraindicated for Melanotan II: Melanotan II affects cardiovascular function and can cause nausea and flushing. Heart disease patients should avoid use.

Contraindicated for PT-141: PT-141 can cause transient increases in blood pressure. Uncontrolled hypertension increases the risk of cardiovascular events.

Contraindicated for Semax: Semax can influence blood pressure regulation. Patients with uncontrolled hypertension should use caution.

Contraindicated for Melanotan II: Melanotan II can cause blood pressure fluctuations. Patients with uncontrolled hypertension face increased cardiovascular risk.

Contraindicated for Dihexa: Dihexa may influence cardiovascular function. Patients with uncontrolled hypertension should exercise caution.

Contraindicated for AOD-9604: Patients with severe kidney disease may have impaired clearance of AOD-9604 metabolites.

Contraindicated for MOTS-c: Patients with severe kidney disease may have impaired clearance of MOTS-c metabolites.

Contraindicated for 5-Amino-1MQ: Patients with kidney disease may have impaired clearance of 5-Amino-1MQ metabolites.

Contraindicated for SS-31 (Elamipretide): Patients with severe kidney disease may have impaired clearance of SS-31 and its metabolites.

Contraindicated for Retatrutide: Patients with severe kidney disease may have impaired clearance of Retatrutide. Dose adjustment or avoidance may be necessary.

Contraindicated for GHK-Cu: Copper metabolism is heavily dependent on liver function. Patients with liver disease may accumulate copper to toxic levels.

Contraindicated for 5-Amino-1MQ: 5-Amino-1MQ affects metabolic enzyme pathways. Patients with liver disease may experience altered drug metabolism and increased toxicity risk.

Contraindicated for Retatrutide: Retatrutide is metabolized hepatically. Patients with significant liver impairment may experience altered drug levels and increased risk of adverse effects.

Contraindicated for Retatrutide: GLP-1 receptor agonists, including Retatrutide, have been associated with an increased risk of pancreatitis. Patients with a history of pancreatitis should avoid use.

Contraindicated for BPC-157: BPC-157 affects the nitric oxide system and may influence blood clotting. Patients with clotting disorders should avoid use.

Contraindicated for TB-500 (Thymosin Beta-4): TB-500 can influence blood clotting pathways. Patients with clotting disorders or on anticoagulants should avoid use.

Contraindicated for Selank: Selank is derived from tuftsin, which can influence immune and coagulation pathways. Patients with clotting disorders should use caution.

Contraindicated for SS-31 (Elamipretide): SS-31 has been associated with injection site reactions. Patients with known peptide allergies should be monitored.

Contraindicated for KLOW: Multi-component peptide blends carry increased risk of allergic reactions. Patients with known peptide allergies should be monitored.

Contraindicated for GLOW: Multi-component peptide blends carry increased risk of allergic reactions. Patients with known peptide allergies should be monitored.

Contraindicated for Thymosin Alpha-1: Thymosin Alpha-1 directly opposes immunosuppressive medications, potentially causing dangerous drug interactions.

Contraindicated for LL-37: LL-37 stimulates immune responses, potentially opposing immunosuppressive medications.

Contraindicated for KPV: KPV has anti-inflammatory and immune-modulating effects that may interact with immunosuppressive medications.

Current Medications

List all medications, supplements, and treatments you are currently using.

Additional Notes

Medical Disclaimer

This screening questionnaire is for informational and pre-consultation purposes only. It does not constitute medical advice, diagnosis, or a treatment recommendation.

All peptide therapy protocols must be prescribed and supervised by a licensed healthcare provider. The contraindication information provided here is based on general clinical guidelines and may not reflect every individual’s unique medical circumstances.

Peptide therapies are used off-label in many cases. Results vary by individual. Borderfreehealth.com does not guarantee outcomes from any peptide therapy program.

By submitting this form, you acknowledge that a qualified medical professional will review your responses and determine appropriate treatment options. Do not discontinue any current medications or begin any new treatment based solely on the results of this screening.